Key facts
- It has raised $2.4M; the latest was Early Stage VC ($740K) in Nov 2024.
- Notable investors include Centre for Cellular And Molecular Platforms, Endiya Partners, Featherlite Office Systems, Jacesa Investment, Kotak Alternate Assets Managers.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Nkure Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Nkure Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nkure Therapeutics
Developer of anticancer immunotherapies intended to provide affordable natural killer cell-based therapies. The company offers therapies effective against leukemia, multiple myeloma, lymphoma, and solid tumors along with fewer side effects on different patient profiles, enabling healthcare professionals to treat cancer patients effectively.
- Sector
- Healthcare
- HQ
- Bangalore, India
- Founded
- 2022
- Employees
- 10
- Website
- nkure.com/
- Ownership
- Privately Held (backing)
Nkure Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nkure Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nkure Therapeutics in its N-PORT filings yet. We sweep new filings monthly.